David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Medicine and Philosophy 16 (2):139-153 (1991)
Today in Japan psychoactive drugs are widely prescribed for various psychiatric disorders including so-called ‘functional’ disorders. They are undoubtedly effective in relieving various psychological and behavioral symptoms. However, Japan has yet to address some basic questions: (1) uncertainty concerning the cause of various psychiatric functional disorders; (2) unknown factors that affect the function of psychotropic drugs in patients; (3) the difficulty in obtaining objective data concerning the effects of these medications * both on the brain and the psychological symptoms (behavior); and most importantly, (4) due to both the behavioral and organic (brain and CNS) effects of psychoactive drugs, the difficulty in evaluating the risk/benefit ratio between the behavioral (primary) effect and the organic (side) effect. In addition, there are bioethical problems, since these uncertainties tend to permit too broad a range of intention and too many modes of intervention in (a) prescribing and (b) taking psychoactive drugs on the part of therapists and patients, respectively. Though the increased risk of the inappropriate use of these drugs – the non-therapeutic uses, and their over-prescription – has been indicated in other industrialized countries, it has not yet been fully recognized and adequately discussed in Japan. Moreover, it is necessary to establish a sound basis for the ‘somato-psychic’ evaluation of these effects in the context of the physician-patient relationship, including the patient's family and even the broader society. Keywords: bioethics, pharmacological treatment, primary and secondary effects, psychiatric-functional disorders, risk/benefit ratio CiteULike Connotea Del.icio.us What's this?
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
|Through your library||Configure|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Katherine Drabiak-Syed (2011). Reining In the Pharmacological Enhancement Train: We Should Remain Vigilant About Regulatory Standards for Prescribing Controlled Substances. Journal of Law, Medicine and Ethics 39 (2):272-279.
Stephan Schleim (2008). The Risk That Neurogenetic Approaches May Inflate the Psychiatric Concept of Disease and How to Cope with It. Poiesis and Praxis 6 (1-2):79-91.
Jonathan Y. Tsou (2012). Intervention, Causal Reasoning, and the Neurobiology of Mental Disorders: Pharmacological Drugs as Experimental Instruments. Studies in History and Philosophy of Science Part C 43 (2):542-551.
Michael R. Hyman & Richard Tansey (1990). The Ethics of Psychoactive Ads. Journal of Business Ethics 9 (2):105 - 114.
Wayne Hall (2003). Addiction, Neuroscience and Ethics. Addiction 98 (7):867-870.
Ralph Metzner (2005). Psychedelic, Psychoactive, and Addictive Drugs and States of Consciousness. In Mitch Earleywine (ed.), Mind-Altering Drugs: The Science of Subjective Experience. Oxford University Press. 25-48.
Lindsay Cole, Jennifer Kesselheim & Aaron Kesselheim (2012). Ethical Issues in New Drug Prescribing. Journal of Bioethical Inquiry 9 (1):77-83.
Jim F. Pagel (2004). Drug Induced Alterations in Dreaming: An Exploration of the Dream Data Terrain Outside Activation-Synthesis. Behavioral and Brain Sciences 27 (5):702-707.
John Coverdale (1991). A Response to 'Psychoactive Drug Prescribing in Japan'. Journal of Medicine and Philosophy 16 (2):155-157.
Leonid Ivanovich Spivak (1991). Psychoactive Drug Research in the Soviet Scientific Tradition. Journal of Psychoactive Drugs 23 (3):271-281.
Sorry, there are not enough data points to plot this chart.
Added to index2010-08-22
Recent downloads (6 months)0
How can I increase my downloads?